{"id":"atorvastatin-lipinon","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1-2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1487","moleculeType":"Small molecule","molecularWeight":"558.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition leads to decreased hepatic cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:30.892Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Primary prevention of cardiovascular disease"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT05483894","phase":"PHASE2","title":"Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2022-08-01","conditions":"Hepatitis B, Portal Hypertension","enrollment":36},{"nctId":"NCT01285544","phase":"PHASE4","title":"The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-09","conditions":"Dyslipidemia, Cardiovascular Disease, Hypercholesterolemia","enrollment":289},{"nctId":"NCT01751295","phase":"NA","title":"Statin and Post-interventional Coronary Microcirculation Dysfunction","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-12","conditions":"Coronary Artery Disease","enrollment":84},{"nctId":"NCT01081548","phase":"PHASE4","title":"A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-08","conditions":"Hypercholesterolemia","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atorvastatin (Lipinon)","genericName":"Atorvastatin (Lipinon)","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}